Keywords
Clinical manifestations
Obesity
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To identify the general aspects of obesity treatment through the use of liraglutide and its main clinical manifestations with an update on the topic in the national literature. Literature review: The effect resulting from prescribing liraglutide for the treatment of obesity works through the metabolic precursor of a glucagon-like peptide 1 (GLP-1) receptor agonist, which means it mimics the action of a natural hormone called GLP -1. GLP-1 helps regulate blood sugar levels by increasing insulin secretion, reducing glucagon production, and slowing gastric emptying. Clinical manifestations evolve with transient gastrointestinal adverse reactions, including nausea, vomiting and diarrhea. Furthermore, there are other manifestations presented in the literature, such as cholelithiasis and cholecystitis, as well as thyroid diseases and increased heart rate. Final considerations: Clinical manifestations resulting from the use of liraglutide for the treatment of obesity are relatively rare, but very underdiagnosed. These are extremely important clinical conditions, mainly due to the recognition of metabolic changes, and must be recognized by health professionals. Early diagnosis of clinical manifestations and effective treatment prevents damage to various organs, reducing the harmfulness of medication in the treatment of obesity.
References
Associação Brasileira para o Estudo da Obesidade e da Síndrome Metabólica (ABESO). Diretrizes Brasileiras de Obesidade. 4. ed. São Paulo: ABESO, 2016; 7-150. Disponível em: https://abeso.org.br/wp-content/uploads/2019/12/Diretrizes-Download-Diretrizes-Brasileiras-de- Obesidade-2016.pdf . Acessado em: 29 de dezembro de 2023.
BRASIL. Pesquisa Nacional de Saúde (PNS) 2019. Disponível em: https://agenciadenoticias.ibge.gov.br/agencia-noticias/2012-agencia-denoticias/noticias/29204-um-em- cada-quatro-adultos-do-pais-estava-obeso-em-2019 . Acessado em 30 de novembro de 2023.
BRASIL. Portaria n. 425, de 19 de Março de 2013. Anexo I: Diretrizes gerais para o tratamento cirúrgico da obesidade e acompanhamento pré e pós-cirurgia bariátrica. Diário of da União [Internet]. 2013;71(1):59. Disponível em: http://www.sgc.goias.gov.br/upload/arquivos/2016-07/portaria-425-de- 19_03_13.pdf . Acessado em 29 de dezembro de 2023.
CANELAS ETC, et al. Implementação farmacoterapêutica do uso da liraglutida. Revista Ibero-Americana de Humanidades, Ciências e Educação, 2023; 9(8): 798-808
CARVALHO D, et al. Agonistas dos receptores do GLP-1 no tratamento da diabetes tipo 2. Revista Portuguesa de Diabetes, 2016; 11(4) 154-166.
CASTRO BR, et al. Segurança e eficácia da semaglutida, liraglutida e sibutramina no auxílio do tratamento da obesidade. Revista Ibero-Americana de Humanidades, Ciências e Educação, 2022; 8(5): 2925-2941.
CONITEC - Comissão Nacional de Incorporação de Tecnologias em Saúde (BR). Protocolo Clínico e Diretrizes Terapêuticas do Sobrepeso e Obesidade em Adultos [Internet]. Brasília: Ministério da Saúde; 2020. Disponível em: http://conitec.gov.br/images/Protocolos/20201113_PCDT_Sobrepeso_e_Obesidade_em_Adultos_29_10 _2020_Final.pdf . Acessado em: 01 de janeiro de 2024.
CORNIER MA. A Review of Current Guidelines for the Treatment of Obesity. American Journal of Managed Care, 2022; 28: pS288.
COZMA MA, et al. Implications of Type 2 Diabetes Mellitus in Patients with Acute Cholangitis: A Systematic Review of Current Literature. In: Healthcare. MDPI, 2022; 11: 2196- 2200.
FUJISHIMA Y, et al. Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes. Cardiovascular diabetology, 2012; 11(1): 1-8.
JUNIOR ES, et al. Abordagem diagnóstica e tratamento da colecistite aguda: uma revisão narrativa. Revista Eletrônica Acervo Saúde, 2021; 13(9): e8772.
LI Z, et al. Transdermal drug delivery systems and their use in obesity treatment. International Journal of Molecular Sciences, 2021; 22(23): 12754.
MELO IC, et al. A incidência de Colecistite Aguda em pacientes com Diabetes Mellitus tipo 2. Revista Eletrônica Acervo Médico, 2023; 23(1): e11928.
PERADZE N, et al. Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial. Cardiovascular diabetology, 2019: 18(1): 1-12.
PORTO CC. Clínica médica na prática diária. 2ª Edição, Barueri: Guanabara Koogan, 2022; 1704p.
SHYANGDAN DS, et al. Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. BMC endocrine disorders, 2010: 10(1): 1-26.
TAHA MIA, et al. Fatores preditivos de colelitíase em obesos mórbidos após astroplastia em Y de Roux.
Revista da Associação Médica Brasileira, 2006; 52: 430-434.
VERMA S, et al. Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: results of the Leader and Sustain 6 trials. Diabetes, Obesity and Metabolism, 2020; 22(12): 2487-2492.
WANDERLEY EN, FERREIRA V. Obesidade: uma perspectiva plural. Ciência & saúde coletiva, 2010; 15: 185-194.
YABE D, SEINO Y. Liraglutide in adults with type 2 diabetes: global perspective on safety, efficacy and patient preference. Clinical Medicine Insights: Endocrinology and Diabetes, 2011; 4: S5976.
YUAN S, et al. Obesity, type 2 diabetes, lifestyle factors, and risk of gallstone disease: a Mendelian randomization investigation. Clinical gastroenterology and hepatology, 2022; 20(3): e529-e537.